Karyn Dyehouse, MD
Medical Oncology · Seneca, SCNPI 1649297094
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.9%), consulting fees and other — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AstraZeneca at 28.6% of the total. Reporting peaked in 2024 at $3,014 and has fallen 53.4% since, to $1,403 in 2025.
Across 157 payments — averaging $57.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$462
- Gilead$455
- Merck$393
- Bayer$255
- plus $3K from 31 others
Across 258 payments — averaging $1691.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$389K
- AstraZeneca$35K
- Eli Lilly$12K
What the payments were for
- Consulting fees$2,06523%
- Food & beverage$5,32059%
- Education$1522%
- Other$1,49717%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $2,580 |
| Novartis | 28 | $1,768 |
| E.r. Squibb & Sons, L.L.C. | 13 | $462 |
| Gilead(2 entities) | 11 | $455 |
| Merck | 8 | $393 |
| Bayer | 11 | $255 |
| Incyte Corporation | 5 | $241 |
| Amgen | 8 | $238 |
| Stemline Therapeutics Inc. | 4 | $208 |
| Lilly USA, LLC | 4 | $175 |
| Galvanize Therapeutics, Inc | 1 | $172 |
| Seagen Inc. | 4 | $168 |
| Rigel Pharmaceuticals, Inc. | 3 | $160 |
| Genentech USA, Inc. | 3 | $153 |
| Ipsen Biopharmaceuticals, Inc | 1 | $145 |
| Daiichi Sankyo Inc. | 6 | $144 |
| Sobi, Inc | 3 | $140 |
| Foundation Medicine, Inc. | 2 | $139 |
| Beigene USA, Inc. | 3 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Puma Biotechnology, Inc. | 2 | $108 |
| Sanofi | 1 | $101 |
| Pfizer | 4 | $77 |
| Karyopharm Therapeutics Inc. | 1 | $71 |
| Blueprint Medicines Corporation | 1 | $70 |
| Bristol Myers Squibb | 2 | $50 |
| Novocure Inc. | 1 | $48 |
| Eisai Inc. | 2 | $46 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $40 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| G1 Therapeutics, Inc. | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $15 |
| Sirtex Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,034 in reported general payments places this provider in the 75th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 68 | $1,050,885 |
| RevlimidLenalidomide | 43 | $621,918 |
| TibsovoIvosidenib | 12 | $378,821 |
| ImbruvicaIbrutinib | 18 | $287,551 |
| InlytaAxitinib | 16 | $277,266 |
| PomalystPomalidomide | 11 | $257,371 |
| Lenalidomide | 24 | $217,817 |
| CalquenceAcalabrutinib Maleate | 16 | $206,018 |
| XtandiEnzalutamide | 13 | $178,397 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $176,327 |
| TafinlarDabrafenib Mesylate | 12 | $162,404 |
| Abiraterone Acetate | 14 | $86,989 |
| EliquisApixaban | 39 | $27,065 |
| Exemestane | 69 | $6,464 |
| Anastrozole | 337 | $6,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis | $77 | $1,355,216123 claims |
| Bristol Myers SquibbRevlimid | $50 | $621,91843 claims |
| NovartisMekinist, Tafinlar | $1,768 | $338,73124 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $462 | $257,37111 claims |
| AstraZenecaCalquence | $2,580 | $206,01816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 medical oncology providers in South Carolina.
Other medical oncology in Seneca
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Eric NelsonSpartanburg$13K
- Kevin BeckerCharleston$9K
- Alaa MuslimaniRock Hill$9K
- Scott LindhorstCharleston$7K
- Abderrahim KhomaniSpartanburg$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.